As Virginia activists launch a push to decriminalize a wide range of psychedelics in the Commonwealth, two state lawmakers are touting the therapeutic potential of entheogenic substances like psilocybin mushrooms.
At a virtual event organized by the reform group Decriminalize Nature Virginia, Sen. Ghazala Hashmi (D) and Del. Dawn Adams (D) participated as hosts, sharing their perspectives about the growing body of research indicating that psychedelics could be powerful tools to combat conditions like treatment-resistant depression and post-traumatic stress disorder (PTSD).
“One thing that has intrigued me in the process of learning myself is the kind of tremendous research that is available that demonstrates that these particular plant based medicines have the capacity to heal, to help and assist people in ways that other medicines often cannot do,” Hashmi said.
Adams, for her part, said she’s “spent a lot of time studying plant medicine, particularly psilocybin” and she reached the conclusion that “it offers unique and extraordinary paths to help people out of things like fear at the end of life and refractory depression and PTSD.”
“I think it is time for these types of treatments to be available.”
At least one member of the Richmond City Council also attended the event—a city in which activists are hoping to see local reform advance as they work to enact a statewide policy change.
Separately, a joint resolution introduced earlier this year by Del. Sally Hudson (D), HJ 530, would task the state Crime Commission with studying alternative approaches to drug enforcement, “including decriminalization of the possession of substances.” It did not advance during the 2021 session, however.
Meanwhile, advocates across the country are hard at work pushing for psychedelics reform.
Last month, for example, Detroit voters approved a ballot initiative to widely decriminalize psychedelics, making it the latest in a growing number of jurisdictions to enact the reform.
In October, lawmakers in a fourth Massachusetts city, Easthampton, voted in favor of a resolution urging the decriminalization of certain entheogenic substances and other drugs.
The action comes months after the neighboring Northampton City Council passed a resolution stipulating that no government or police funds should be used to enforce laws criminalizing people for using or possessing entheogenic plants and fungi. Elsewhere in Massachusetts, Somerville and Cambridge have also moved to effectively decriminalize psychedelics.
The local measures also express support for two bills introduced in the Massachusetts state legislature this year. One would remove criminal penalties for possession of all currently illicit drugs and the other would establish a task force to study entheogenic substances with the eventual goal of legalizing and regulating the them.
Separately, Seattle’s City Council approved a resolution in October to decriminalize noncommercial activity around a wide range of psychedelic substances, including the cultivation and sharing of psilocybin mushrooms, ayahuasca, ibogaine and non-peyote-derived mescaline.
A bill to legalize psychedelics in California advanced through the Senate and two Assembly committees this year before being pulled by the sponsor to buy more time to generate support among lawmakers. The plan is to take up the reform during next year’s second half of the legislative session, and the senator behind the measure says he’s confident it will pass.
California activists were separately cleared to begin collecting signatures for a historic initiative to legalize psilocybin mushrooms in the state. Oakland, Santa Cruz and Arcata have already enacted psychedelics decriminalization.
In Oakland, the first city where a city council voted to broadly deprioritize criminalization of entheogenic substances, lawmakers approved a follow-up resolution in December that calls for the policy change to be adopted statewide and for local jurisdictions to be allowed to permit healing ceremonies where people could use psychedelics. Activists in the city are also hoping to expand upon the local decriminalization ordinance by creating a community-based model through which people could legally purchase entheogenic substances from local producers.
Earlier this year, Texas enacted a law directing state officials to study psychedelics’ medical value.
The governor of Connecticut signed a bill in June that includes language requiring the state to carry out a study into the therapeutic potential of psilocybin mushrooms.
Oregon voters passed a pair of initiatives last November to legalize psilocybin therapy and decriminalize possession of all drugs. On the local level, activists in Portland are mounting a push to have local lawmakers pass a resolution decriminalizing the cultivation, gifting and ceremonial use of a wide range of psychedelics.
The top Democrat in the Florida Senate filed a bill in September that would require the state to research the medical benefits of psychedelics such as psilocybin and MDMA.
A New York lawmaker introduced a bill in June that would require the state to establish an institute to similarly research the medical value of psychedelics.
The Maine House of Representatives passed a drug decriminalization bill this year, but it later died in the Senate.
Meanwhile, Denver activists who successfully led the 2019 campaign to make the city the first in the U.S. to decriminalize psilocybin possession have set their eyes on broader reform, with plans in the works to end the criminalization of noncommercial gifting and communal use of the psychedelic.
In a setback for advocates, the U.S. House of Representatives recently voted against a proposal from Rep. Alexandria Ocasio-Cortez (D-NY) that would have removed a spending bill rider that advocates say has restricted federal funds for research into Schedule I drugs, including psychedelics such as psilocybin, MDMA and ibogaine. However, it picked up considerably more votes this round than when the congresswoman first introduced it in 2019.
Report provisions of separate, House-passed spending legislation also touch on the need to expand cannabis and psychedelics research. The panel urged the National Institute on Drug Abuse (NIDA) to support expanded marijuana studies, for example. It further says that federal health agencies should pursue research into the therapeutic potential of psychedelics for military veterans suffering from a host of mental health conditions.
There was an attempt by a Republican congressman to attach language into a defense bill that would promote research into psychedelics therapy for active duty military members, but it was not made in order in the House Rules Committee in September.
NIDA also recently announced it’s funding a study into whether psilocybin can help people quit smoking cigarettes.
An official with the U.S. Department of Veterans Affairs also said at a recent congressional hearing that the agency is “very closely” following research into the potential therapeutic benefits of psychedelics like MDMA for military veterans.
For what it’s worth, Rep. Earl Blumenauer (D-OR), a longstanding champion of marijuana reform in Congress, said in October that he intends to help bring the psychedelics reform movement to Capitol Hill “this year.”
In May, lawmakers in Congress filed the first-ever legislation to federally decriminalize possession of illicit substances.
White House Drug Czar Open To Safe Consumption Sites For Illegal Substances Amid Overdose Crisis
Photo elements courtesy of carlosemmaskype and Apollo.